SCHEMBL21054341

SCHEMBL21054341

Cc1cccc(/C=N/Nc2nc(N3CCOCC3)c3[nH]c(C(=O)Nc4cccnc4)nc3n2)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIKFYVE Q9Y2I7 10/20 0.58
CHEK1 O14757 2/20 0.44
PIK3CD O00329 2/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
AKT1 P31749 2/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TEX264 Q9Y6I9 1/20 0.41
MTOR P42345 2/20 0.40
PIK3CA P42336 2/20 0.40
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30312366 1.00 PIKFYVE (0.58) PIKFYVECHEK1PIK3CDLMNAMAPT
SCHEMBL30312519 0.92 PIKFYVE (0.68) PIKFYVECHEK1PIK3CDLMNAMAPT
SCHEMBL21054816 0.92 PIKFYVE (0.68) PIKFYVECHEK1PIK3CDLMNAMAPT
SCHEMBL21053866 0.92 PIKFYVE (0.60) PIKFYVECHEK1PIK3CDLMNAMAPT
SCHEMBL30312468 0.92 PIKFYVE (0.60) PIKFYVECHEK1PIK3CDLMNAMAPT
SCHEMBL24100563 0.88 KDM4E (0.49) PIKFYVEPIK3CDLMNAMAPTKDM4E
SCHEMBL21054720 0.87 PIKFYVE (0.57) PIKFYVECHEK1PIK3CDLMNAMAPT
SCHEMBL30312343 0.87 PIKFYVE (0.57) PIKFYVECHEK1PIK3CDLMNAMAPT
SCHEMBL21054116 0.87 PIKFYVE (0.62) PIKFYVECHEK1LMNAMAPTKDM4E
SCHEMBL30312546 0.87 PIKFYVE (0.62) PIKFYVECHEK1LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11603372-B2 Compounds and therapeutic uses thereof VIOGEN BIOSCIENCES, LLC (US) 2023-03-14 US claimed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US claimed
WO-2019113523-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF BAJJI ASHOK (US) 2019-06-13 WO claimed
US-11603372-B2 Compounds and therapeutic uses thereof VIOGEN BIOSCIENCES, LLC (US) 2023-03-14 US disclosed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US disclosed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603372-B2 Compounds and therapeutic uses thereof IL15, IL17A, IL2 PIKFYVE 944/4885CHEK1 4610/4885PIK3CD 1995/4885
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF IL15, IL17A, IL2 PIKFYVE 944/4885CHEK1 4610/4885PIK3CD 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.